脓毒症与脓毒性休克复苏的心血管决定因素
研究纳入55例按存活脓毒症指南(SSG)复苏的脓毒症患者,在扩容前、后及需要时加用去甲肾上腺素和多巴酚丁胺时测量MAP、CI、Pra、PPV、SVV、Eadyn、Ea、Ees、VAC、LVeff、Pmsa、Pvr和Eh。所有患者入院时低血压(MAP 56.8 ± 3.1 mmHg)、心动过速(113.1 ± 7.5 次/分)、乳酸升高(5.0 ± 4.2 mmol/L)且VAC恶化,74%患者CI > 2 L/min/m²,28天死亡率48%,与入院乳酸、BUN和肌酐相关而与心血管状态无关。扩容后MAP和CI改善、Ees升高、HR和Ea降低使VAC正常化,CI增加与基线PPV、SVV成比例;扩容使35/55例MAP > 65 mmHg。作者认为对SSG复苏的心血管反应高度异质但可从治疗前心血管状态预测。
要点
- 55例脓毒症患者按SSG复苏,入院MAP 56.8 ± 3.1 mmHg、心率113.1 ± 7.5 次/分、乳酸5.0 ± 4.2 mmol/L,VAC恶化。
- 28天死亡率48%,与入院乳酸、BUN和肌酐相关,与心血管状态无关。
- 扩容后MAP和CI改善、Ees升高、HR和Ea降低使VAC正常化;CI增加与基线PPV、SVV成比例,CI增加成比例降低PPV和SVV。
- 扩容使MAP > 65 mmHg达35/55例;MAP有反应者PPV、SVV和Eadyn高于无反应者。
- NE用于20/55例脓毒性休克患者,仅12例MAP升至>65 mmHg;NE增加Ea、Eadyn、Pra、Pmsa和VAC,降低HR、PPV、SVV和LVeff。
适用人群与场景
- 55例按存活脓毒症指南(SSG)治疗的脓毒症患者,研究在扩容前、扩容后以及需要时加用去甲肾上腺素和多巴酚丁胺时进行测量。
处置流程与药物剂量
- 按SSG进行复苏:先扩容(VE),若需要再加用去甲肾上腺素(NE),仍低血压者加用多巴酚丁胺。
- 去甲肾上腺素用于20/55例脓毒性休克患者,其中12例MAP升至>65 mmHg。
- 多巴酚丁胺用于去甲肾上腺素后仍低血压的8例患者中的6例,可增加Ees、MAP、CI和LVeff,降低HR、Pra和VAC。
研究设计与关键结果
- 研究类型为对55例按SSG治疗的脓毒症患者的前后测量研究;所有患者低血压(MAP 56.8 ± 3.1 mmHg)、心动过速(113.1 ± 7.5 次/分)、乳酸升高(5.0 ± 4.2 mmol/L)且VAC恶化,CI可变但74%患者> 2 L/min/m²。
- 28天死亡率为48%,与入院乳酸、BUN和肌酐水平相关,与心血管状态无关。
- 扩容后所有患者MAP和CI改善、心肌收缩力(Ees)改善,Pra、Pmsa和Pvr改善,HR和Ea降低使VAC正常化;CI增加与基线PPV和SVV成比例,CI增加成比例降低PPV和SVV。
- 扩容使35/55例患者MAP > 65 mmHg;MAP有反应者PPV、SVV和Eadyn高于无反应者。
- 去甲肾上腺素增加Ea、Eadyn、Pra、Pmsa和VAC,降低HR、PPV、SVV和LVeff;MAP有反应者去甲肾上腺素前Ees更高、VAC更低。
- 在所有时间点和方案所有步骤,CI变化与Pvr变化成比例,且不依赖于治疗。
证据类型、等级与局限
- 证据类型:对55例脓毒症患者的前后测量研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对SSG复苏的心血管反应高度异质,但可从治疗前测量的心血管状态预测,提示临床可根据治疗前PPV、SVV、Eadyn、Ees和VAC等指标预判扩容和血管活性药的反应。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: We hypothesized that the cardiovascular responses to Surviving Sepsis Guidelines (SSG)-defined resuscitation are predictable based on the cardiovascular state.
METHODS: Fifty-five septic patients treated by SSG were studied before and after volume expansion (VE), and if needed norepinephrine (NE) and dobutamine. We measured mean arterial pressure (MAP), cardiac index (CI), and right atrial pressure (Pra) and calculated pulse pressure and stroke volume variation (PPV and SVV), dynamic arterial elastance (Eadyn), arterial elastance (Ea) and left ventricular (LV) end-systolic elastance (Ees), Ees/Ea (VAC), LV ejection efficiency (LVeff), mean systemic pressure analogue (Pmsa), venous return pressure gradient (Pvr), and cardiac performance (Eh), using standard formulae.
RESULTS: All patients were hypotensive (MAP 56.8 ± 3.1 mmHg) and tachycardic (113.1 ± 7.5 beat min-1), with increased lactate levels (lactate = 5.0 ± 4.2 mmol L-1) with a worsened VAC. CI was variable but > 2 L min-1 M-2 in 74%. Twenty-eight-day mortality was 48% and associated with admission lactate, blood urea nitrogen (BUN), and creatinine levels but not cardiovascular state. In all patients, both MAP and CI improved following VE, as well as cardiac contractility (Ees). Fluid administration improved Pra, Pmsa, and Pvr in all patients, whereas both HR and Ea decreased after VE, thus normalizing VAC. CI increases were proportional to baseline PPV and SVV. CI increases proportionally decreased PPV and SVV. VE increased MAP > 65 mmHg in 35/55 patients. MAP responders had higher PPV, SVV, and Eadyn than non-responders. NE was given to 20/55 patients in septic shock, but increased MAP > 65 mmHg in only 12. NE increased Ea, Eadyn, Pra, Pmsa, and VAC while decreasing HR, PPV, SVV, and LVeff. MAP responders had higher pre-NE Ees and lower VAC. Dobutamine was given to 6/8 patients who remained hypotensive following NE. It increased Ees, MAP, CI, and LVeff, while decreasing HR, Pra, and VAC. At all times and all steps of the protocol, CI changes were proportional to Pvr changes independent of treatment.
CONCLUSIONS: The cardiovascular response to SSG-based resuscitation is highly heterogeneous but predictable from pre-treatment measures of cardiovascular state.
参考来源
- Guarracino F, Bertini P, Pinsky MR, et al. Cardiovascular determinants of resuscitation from sepsis and septic shock. Crit Care. 2019. PMID: 30987647. doi:10.1186/s13054-019-2414-9
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。